FIG. 1



Dose level 150 mg/m2, (mean, SD)
Plasma conc (ng/mL)
10000
1000
100
10
1
0
5
10
15
20
25
Time (hour)
17-AAG
17-AG

FIG. 2



Dose level 220 mg/m2, (mean, SD)
Plasma conc (ng/mL)
10000
1000
100
10
1
0
5
10
15
20
25
Time (hour)
17-AAG
17-AG

FIG. 3



Dose level 275 mg/m2 , (mean, SD)
10000
1000
100
10
1
Plasma conc (ng/mL)
0
5
10
15
20
25
Time (hour)
17–AAG
17–AG

FIG. 4



Dose level 275 mg/m2 , Day 1 and Day 11 (mean, split X–axis)
10000
1000
100
10
1
Plasma conc (ng/mL)
0
5
10
20
25
Time (hour)
17–AAG Day 1
17–AG Day 1
17–AAG Day 11
17–AG Day 11

FIG. 5





FIG. 6



AUC 17-AAG f(x)=7.20E+1*x+-5.91E+3 | AUC 17-AG f(x)=4.48E+1*x+-3.27E+3

FIG. 7



Cmax Day 1 and Day 11 (Banerji, et al.) vs. data from this study (Example 2)
Cmax D1 Banerji 17-AAG
Cmax D8 Banerji 17-AAG
Cmax D1 Banerji 17-AG
Cmax D8 Banerji 17-AG
Present Study 17-AAG
Present Study 17-AG
Cmax (ng/mL)
12000
10000
8000
6000
4000
2000
0
0 50 100 150 200 250 300 350 400 450
Dose Level (mg/m2)

FIG. 8



AUCtotal for six dose levels in Banerji et al. (2002) compared to Example 2
Banerji
Present Study
AUCtotal (ng/mL*H)
35000
30000
25000
20000
15000
10000
5000
0
0 50 100 150 200 250 300 350
Dose Level (mg/m2)

FIG. 9




FIG. 10





FIG. 11A






FIG. 11B







FIG. 12


Percent change in serum M-spike and urine M-protein of a patient (150 mg/m^2 dose level)



	Baseline	Post Cycle 1	Post Cycle 2	Post Cycle 3	End of Study
M-Spike (mg/dL)	1770	ND	1190	1290	2240
Urine M-Protein (mg/24h)	317	245	187	ND	1598

FIG. 13

Percent change in serum M-spike and total IgG of a patient (275 mg/m^2 dose level)



	Baseline	Post C1	Post C2	Post C3	Post C4	Post C5	Post C6	Post C7	End Study
M-Spike (g/dL)	2.45	2.24	2.51	2.38	2.18	2.24	2.25	2.24	2.18
Total Ig G(mg/dl)	3040	2470	2830	2770	2930	2520	2680	2520	2680